Intractable epilepsy

Are the new antiepileptic agents beneficial?

J. Gilman, M. S. Duchowny, T. J. Resnick, P. Jayakar, L. A. Alvarez, P. Dean

Research output: Contribution to journalArticle

Abstract

Intractable childhood epilepsy is a significant cause of medical morbidity and ultimately reduces quality of life. During the 1990s, there has been an unprecedented release of new antiepileptic drugs which act by novel mechanisms and have reduced adverse effects. Felbamate, gabapentin, lamotrigine, and topiramate are in current use in the United States and have been used for a wide spectrum of epileptic disorders. Aplastic anemia and hepatotoxicity now preclude felbamate except in resistant cases. Aside from the intractable partial and generalized epilepsies including the Lennox-Gastaut syndrome, the newer agents are potentially useful in the treatment of secondarily generalized seizures, juvenile myoclonic epilepsy, benign partial epilepsy with centro-temporal spikes, and children with systemic illness taking multiple medications. How these agents will ultimately fit into the overall scheme of treatment of childhood epilepsy and their role as first-line therapy are largely unexplored.

Original languageEnglish
Pages (from-to)98-101
Number of pages4
JournalInternational Pediatrics
Volume12
Issue number2
StatePublished - Dec 1 1997

Fingerprint

felbamate
Anticonvulsants
Partial Epilepsy
Juvenile Myoclonic Epilepsy
Generalized Epilepsy
Aplastic Anemia
Epilepsy
Seizures
Therapeutics
Quality of Life
Morbidity
Drug Resistant Epilepsy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Gilman, J., Duchowny, M. S., Resnick, T. J., Jayakar, P., Alvarez, L. A., & Dean, P. (1997). Intractable epilepsy: Are the new antiepileptic agents beneficial? International Pediatrics, 12(2), 98-101.

Intractable epilepsy : Are the new antiepileptic agents beneficial? / Gilman, J.; Duchowny, M. S.; Resnick, T. J.; Jayakar, P.; Alvarez, L. A.; Dean, P.

In: International Pediatrics, Vol. 12, No. 2, 01.12.1997, p. 98-101.

Research output: Contribution to journalArticle

Gilman, J, Duchowny, MS, Resnick, TJ, Jayakar, P, Alvarez, LA & Dean, P 1997, 'Intractable epilepsy: Are the new antiepileptic agents beneficial?', International Pediatrics, vol. 12, no. 2, pp. 98-101.
Gilman J, Duchowny MS, Resnick TJ, Jayakar P, Alvarez LA, Dean P. Intractable epilepsy: Are the new antiepileptic agents beneficial? International Pediatrics. 1997 Dec 1;12(2):98-101.
Gilman, J. ; Duchowny, M. S. ; Resnick, T. J. ; Jayakar, P. ; Alvarez, L. A. ; Dean, P. / Intractable epilepsy : Are the new antiepileptic agents beneficial?. In: International Pediatrics. 1997 ; Vol. 12, No. 2. pp. 98-101.
@article{991e1f6d1bc14805aae53ea871ac4d13,
title = "Intractable epilepsy: Are the new antiepileptic agents beneficial?",
abstract = "Intractable childhood epilepsy is a significant cause of medical morbidity and ultimately reduces quality of life. During the 1990s, there has been an unprecedented release of new antiepileptic drugs which act by novel mechanisms and have reduced adverse effects. Felbamate, gabapentin, lamotrigine, and topiramate are in current use in the United States and have been used for a wide spectrum of epileptic disorders. Aplastic anemia and hepatotoxicity now preclude felbamate except in resistant cases. Aside from the intractable partial and generalized epilepsies including the Lennox-Gastaut syndrome, the newer agents are potentially useful in the treatment of secondarily generalized seizures, juvenile myoclonic epilepsy, benign partial epilepsy with centro-temporal spikes, and children with systemic illness taking multiple medications. How these agents will ultimately fit into the overall scheme of treatment of childhood epilepsy and their role as first-line therapy are largely unexplored.",
author = "J. Gilman and Duchowny, {M. S.} and Resnick, {T. J.} and P. Jayakar and Alvarez, {L. A.} and P. Dean",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "12",
pages = "98--101",
journal = "International Pediatrics",
issn = "0885-6265",
publisher = "Miami Children's Hospital Medical Journal Inc.",
number = "2",

}

TY - JOUR

T1 - Intractable epilepsy

T2 - Are the new antiepileptic agents beneficial?

AU - Gilman, J.

AU - Duchowny, M. S.

AU - Resnick, T. J.

AU - Jayakar, P.

AU - Alvarez, L. A.

AU - Dean, P.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Intractable childhood epilepsy is a significant cause of medical morbidity and ultimately reduces quality of life. During the 1990s, there has been an unprecedented release of new antiepileptic drugs which act by novel mechanisms and have reduced adverse effects. Felbamate, gabapentin, lamotrigine, and topiramate are in current use in the United States and have been used for a wide spectrum of epileptic disorders. Aplastic anemia and hepatotoxicity now preclude felbamate except in resistant cases. Aside from the intractable partial and generalized epilepsies including the Lennox-Gastaut syndrome, the newer agents are potentially useful in the treatment of secondarily generalized seizures, juvenile myoclonic epilepsy, benign partial epilepsy with centro-temporal spikes, and children with systemic illness taking multiple medications. How these agents will ultimately fit into the overall scheme of treatment of childhood epilepsy and their role as first-line therapy are largely unexplored.

AB - Intractable childhood epilepsy is a significant cause of medical morbidity and ultimately reduces quality of life. During the 1990s, there has been an unprecedented release of new antiepileptic drugs which act by novel mechanisms and have reduced adverse effects. Felbamate, gabapentin, lamotrigine, and topiramate are in current use in the United States and have been used for a wide spectrum of epileptic disorders. Aplastic anemia and hepatotoxicity now preclude felbamate except in resistant cases. Aside from the intractable partial and generalized epilepsies including the Lennox-Gastaut syndrome, the newer agents are potentially useful in the treatment of secondarily generalized seizures, juvenile myoclonic epilepsy, benign partial epilepsy with centro-temporal spikes, and children with systemic illness taking multiple medications. How these agents will ultimately fit into the overall scheme of treatment of childhood epilepsy and their role as first-line therapy are largely unexplored.

UR - http://www.scopus.com/inward/record.url?scp=0031402157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031402157&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 98

EP - 101

JO - International Pediatrics

JF - International Pediatrics

SN - 0885-6265

IS - 2

ER -